Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Figure out how to Perceive Warnings while Looking for an Auto Collision Lawyer - 2Staggering Spots to Stargaze All over the Planet
- 3What we know about the 'Stranger Things' spinoff — plus the one cast member who guessed it correctly
- 4I spent the last year transforming my life. Becoming a Rockette for a day made me confront a fear I couldn't shake.
- 5Make your choice for the PS5 game that you love playing with companions!
- Step by step instructions to Figure out the Natural Effect of 5G Pinnacles
- 6 Well known Nissan Vehicles in the U.S.
- Brazilian cardinal orders a popular Catholic priest to go offline following right-wing attacks
- Journeys That could only be described as epic: Delightful Voyage Lines All over the Planet
- Audits of the Top Science fiction Movies This Year
- When darkness shines: How dark stars could illuminate the early universe
- As cases of a rare, deadly infection rise, doctors worry fewer teens will get vaccinated
- Seven deaths possibly linked to malfunctioning glucose monitors
- How to avoid or deal with an outrageous medical bill
